Cancer Risks

PALB2 Summary Cancer Risk Table

CANCER TYPE GENETIC CANCER RISK
Female Breast High Risk 
Male Breast Elevated Risk
Ovarian Elevated Risk
Pancreatic Elevated Risk

PALB2 gene Cancer Risk Table

 

 

CANCER TYPE AGE RANGE CANCER RISK RISK FOR GENERAL POPULATION
Female Breast To age 50 17% 1.9%
  To age 80 53% 10.2%
Pancreatic To age 80 2%-3% 1%
Ovarian To age 80 5% 1.0%
Male Breast To age 80 1% 0.1%

PALB2 Cancer Risk Management Table

CANCER TYPE PROCEDURE AGE TO BEGIN FREQUENCY

(UNLESS OTHERWISE INDICATED BY FINDINGS)

Female Breast Breast awareness – Women should be familiar with their breasts and promptly report changes to their healthcare provider. Periodic, consistent breast self-examination (BSE) may facilitate breast awareness. Individualized NA
  Clinical encounter, including clinical breast exam, ongoing risk assessment and risk reduction counseling. When genetic risk is identified Every 6 to 12 months
  Mammography with consideration of tomosynthesis and breast MRI with contrast Age 30, or modified to a younger age based on family history Annually
  Consider risk-reducing mastectomy. Individualized NA
  Consider additional risk-reduction strategies. Individualized NA
Pancreatic For patients with a family history of pancreatic cancer, consider available options for pancreatic cancer screening, including the possibility of endoscopic ultrasonography (EUS) and MRI/magnetic resonance cholangiopancreatography (MRCP). It is recommended that patients who are candidates for pancreatic cancer screening be managed by a multidisciplinary team with experience in screening for pancreatic cancer, preferably within research protocols. Age 50, or 10 years younger than the earliest age of pancreatic cancer diagnosis in the family Annually
  Provide education about ways to reduce pancreatic cancer risk, such as not smoking and losing weight. Individualized Individualized
Ovarian Currently there are no specific medical management recommendations for ovarian cancer risk in mutation carriers. NA NA
Male Breast Currently there are no specific medical management guidelines for breast cancer risk in mutation carriers. However, the increase in risk warrants consideration of options for male breast cancer screening, such as patient breast awareness education and clinical breast examinations. Individualized NA
For Patients With A Cancer Diagnosis For patients with a gene mutation and a diagnosis of cancer, targeted therapies may be available as a treatment option for certain tumor types (e.g., platinum chemotherapy, PARP-inhibitors) NA NA

Unique Challenges and Issues